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was 2 at ≥ 6 months follow-up. 1 DPBN-patient had G3 
xerostomia at month 3 that reduced to G1 thereafter. 
Conclusions; There were no local recurrences in the DPBN-
group. We did not observe significant differences in LC, RC, 
DC or OS until now. Due to mucosal LT, the DPBN-DPP has 
been adapted. Since then, no G4 mucosal LT was observed. 
Another 66 patients will be recruited for the study.  
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Purpose/Objective: Concurrent cisplatin and radiation (cisp-
RT) can achieve high locoregional control and survival for 
locally advanced head and neck cancer (LAHNC) particularly 
in the oropharynx, HPV+, and non-smokers. Recent 
retrospective reviews challenge the role of cetuximab plus 
radiation in this population suggesting inferior outcomes, 
which needs to be further confirmed. HPV negative head and 
neck cancer patients seem to do far worse with current 
strategies. This study compares concurrent cisp-RT with 
radiation plus anti-EGFR moAb (anti-EGFR-RT) in LAHNC in a 
population that is mainly HPV negative. The prognostic value 
of HER3 pathway-related biomarkers is explored. 
Materials and Methods: From 1999 to 2010, 108 LAHNC 
patients with oral cavity, oropharynx, hypopharynx or larynx 
tumors received definitive treatment with cisp-RT (n= 71) or 
anti-EGFR-RT (n=37). Of these, 86 patients had tissue 
available for HPV analysis (PCR and p16), and 48 for HER3 
pathway analysis. Outcomes were analyzed by the Kaplan-
Meier method, Cox model and competing-risks analysis tools. 
Results: 88% of the analyzed samples were HPV negative. 
Patient characteristics include 77% smokers, 70% heavy 
alcohol intake, 49% T4 and 69% N2-3. The anti-EGFR-RT 
patients were older. At a median follow-up of 4.2 years, the 
2- and 5-year locoregional failure rates were 34.1% and 41.8% 
for cisp-RT vs 60.1% and 71.5% for anti-EGFR-RT (p=0.015). 
These differences remained significant for progression-free 
survival (p=0.0006) and were lost when distant metastasis 
was the only site of relapse (p=0.24). Metastasis-only relapse 
occurred in 14.8% of patients. In multivariate analysis, cisp-
RT predicted for locoregional relapse (HR=0.53, 95%CI: 0.31-
0.92, p=0.024) and progression-free survival (HR=0.44, 95%CI: 
0.27-0.71, p=0.0009), whereas hypopharynx/larynx primaries 
(HR=5.13, 95%CI: 1.50-17.51, p=0.013) and T4 tumors 
(HR=2.95, 95%CI: 1.05-8.31, p=0.041) predicted for 
metastasis-only relapse. Subgroup analysis of HER3 pathway-
related biomarkers adjusted for significant risk variables 
identified overexpression of pS6 (p=0.009) and p53 (p=0.049) 
as prognostic for locoregional failure, and pS6 (p=0.016) and 
HER3 (p=0.049) expression for metastasis-only relapse.  
Conclusions: Superior outcomes with concurrent cisp-RT in 
LAHN patients are observed in a predominantly HPV negative 
population. It is of clinical relevance that 
hypopharynx/larynx primaries and T4 tumors predicted for 
metastasis as the only site of relapse in such a high risk 
group. Exploratory analyses suggest that pS6 and p53 
expression predict for locoregional failure and that pS6 and 
HER3 do for metastasis-only relapse. 
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Purpose/Objective: Data quality of routine patients is of 
vital importance when creating an infrastructure for rapid 
learning. The aim of this work is to provide a platform that 
enables rapid learning for laryngeal carcinoma patients and 
prove the clinical relevance of a survival prediction model as 
a first step to multi institutional rapid learning. In this study 
we present a first rapid learning approach that combines 
learning a decision support system from MAASTRO Clinic 
('training cohort') and validating it in both the Illawarra 
Cancer Care Centre ('clinical cohort') and the RTOG-91-11 
clinical trial dataset ('trial cohort'). 
Materials and Methods: Data extraction and mining tools 
were used to collect the input parameters from the clinical 
cohort's OIS system (MosaiQ). The training cohort was used to 
determine the prognosis range for good, medium and poor 
prognosis patients so it could be applied to the clinical cohort 
and to validate the new implementation of the model. To 
evaluate the model performance the Area Under the Curve 
(AUC) spread for each dataset was calculated using 
bootstrapping. A similar approach was applied to the 
radiotherapy only arm of the trial cohort. The resulting 
Kaplan-Meier survival curves for the good, medium and poor 
prognosis groups are displayed for each separate cohort. 
Results: Data mining identified 125 laryngeal carcinoma 
patients, resulting in 109 that were eligible to be evaluated 
by the model to predict 2 year survival. Bootstrapping 
resulted in a normally distributed AUC reliability interval 
(95% CI) of 0.61 to 0.84, 0.47 to 0.67 and 0.74 to 0.82 for the 
clinical, trial and training cohorts respectively. The predicted 
prognostic survival groups resulted in the Kaplan Meier curves 
presented in Figure 1. The survival prediction thresholds to 
create the poor, medium and good prognosis groups were 57% 
and 81% chance of 2 year survival. This resulted in a group 
distribution of 47%, 42% and 11% and 53%, 42% and 5% for the 
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poor, medium and good prognosis group for the clinical 
cohort and trial cohort respectively, while (by definition) the 
training cohort had 25%, 50% and 25% distribution. This means 
the model was able to classify poor and medium prognosis 
patients in the clinical cohort but the good prognosis patient 
group was very small, as the clinical cohort population was 
older, had more advanced cancers, more nodal spread and 
more non-glottic cancers which are unfavorable for the 
survival prognosis. 
 
Figure 1: Kaplan Meier survival curves for the training, 
clinical and trial cohort respectively. 
Conclusions: The technical infrastructure and model is able 
to support the prognosis prediction of laryngeal carcinoma 
patients in clinical cohort which could be used in future to 
personalize treatment, improve treatment quality and 
evaluate these practice changes. The model does not work 
well for the biased patient population in the trial cohort.  
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Purpose/Objective: The aim of the studies was to assess the 
role of telomerase in immortality state of HNSCC cell lines. 
Malignant tumors of the head and neck region differs natural 
clinical outcome and prognosis depending on the histological 
diagnosis and location. Despite that the diagnostic and 
therapeutic problems are similar. The gold standard of 
therapy these tumors, with a view to maximal radicalization 
of treatment, is combined therapy involving the local 
(surgery, radiotherapy) and systemic treatment 
(chemotherapy). Recently, the great interest arouses 
individualization of cytostatics selection, as well as gene 
therapy application. One of the targets is telomerase as the 
enzymatic complex participating in immortality of cancer 
cells. 
Materials and Methods: Knock down of telomerase (TERT 
subunit) by lentiviral vectors encoding shRNA on cancer cell 
lines derivated from HNSCC tumors (head and neck cancers 
are squamous cell carcinoma) and KB cells was carried out. 
The level of silencing was performed by qPCR and 
immunofluorescence staining. The impact of drugs (cisplatin 
and decetaxel) and ionizing radiation on the induction of 
apoptosis, cell cycle, yH2AX and cell proliferation rate via 
immunofluorescence staining, cytometer analysis and qPCR 
was also estimated. The telomere length measurement using 
a method based on qPCR was assessed. 
Results: There was shown an influence of telomerase 
depletion on apoptosis, proliferation rate and yH2AX 
expression both in non-treated control cell lines as on cell 
population after chemoradiotherapy. Moreover, the influence 
of telomerase knock-down on increased chemo-and 
radioresistance in vitro was proved.  
Conclusions: Our results demonstrate increased chemo- and 
radiosensitivity in HNSCC cell lines after telomerase 
silencing. Telomerase is likely to play a pivotal role in 
chemo- and radioresistance of selected HNSCC cell lines, 
however further studies are needed.  
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Purpose/Objective: Lung cancer is the most frequent 
malignant neoplasm with extremely poor prognosis. In 
earliest stages of the disease clinical benefit of radical 
surgical excision is similar to stereotactic body radiotherapy 
(SBRT). The success of high-dose SBRT is certainly related to 
the X-rays-induced apoptosis. However other, not-well 
characterized mechanisms may also contribute. We 
hypothesize that high dose SBRT causes an increase in the 
expression of multipeptide tumor antigens, which further 
may lead to a stimulation of specific immune response. Those 
mechanisms are not fully understood therefore we have 
designed a prospective study to determine radiation-induced 
immune response changes. The protocol was approved by 
Local Ethical Committee.  
Objective: to assess the effect of high dose ionizing radiation 
on changes in the expression of T cell activation markers 
(CD25, CD28, CTLA-4, PD-1) , transcription factors associated 
with Th1, Th2, Th17 and regulatory T cell subpopulations of 
CD4(+) T cells (T-bet, GATA-3, ROR-γt and FoxP3, 
respectively) in patients treated with SBRT for T1/2N0 M0 
NSCLC. 
Materials and Methods: Study group consists of patients with 
newly diagnosed NSCLC stage T1/2N0M0 qualified for SBRT. 
Patients with comorbidities of significant impact on immune 
system are excluded. Peripheral blood samples are collected 
three times from patients: before the treatment (n = 44), 2 
weeks (n = 37) and 12 weeks (n = 21) after SRBT. Expression 
level of selected proteins on peripheral blood lymphocytes is 
measured by flow cytometry. 
Results: The study was started in November 2013. Since then 
44 consented patients were included. SBRT was planned and 
delivered according to the Department’s treatment 
standards. Analysis of blood samples has shown that SRBT 
significantly increases numbers of PD-1(+) and CTLA-4(+) 
